Nonlinear model for acetazolamide.

Area of Science:

• Pharmacokinetics and Drug Metabolism
• Biochemistry
• Physiology

Background:

• Acetazolamide is a carbonic anhydrase inhibitor used clinically.
• Understanding its distribution and binding is crucial for optimizing therapeutic effects.
• Previous models did not fully capture acetazolamide's complex binding characteristics.

Purpose of the Study:

• To develop and validate a nonlinear pharmacokinetic model for acetazolamide in rabbits.
• To characterize acetazolamide's binding to plasma proteins, tissue proteins (including carbonic anhydrase), and red blood cells.
• To correlate drug concentration with pharmacological response.

Main Methods:

• Intravenous bolus injections of 14C-labeled acetazolamide in rabbits.
• Measurement of drug concentrations in plasma, urine, and red blood cells.
• Development of a nonlinear one-compartment model with two tissue-binding parameters using AUTOAN and NONLIN software.
• Simultaneous fitting of plasma, body, and red blood cell drug concentration data.

Main Results:

• A nonlinear model provided a better fit than a linear model, incorporating drug binding to plasma, tissue proteins, and red blood cells.
• Estimated parameters included initial plasma concentration, maximum tissue binding, and dissociation constants.
• Dissociation constants suggested binding to carbonic anhydrase and other red blood cell proteins.
• Dose-dependent correlation was observed for initial plasma concentration and maximum tissue protein binding.

Conclusions:

• The developed nonlinear model accurately describes acetazolamide's disposition and binding in rabbits.
• The model elucidates acetazolamide's interaction with carbonic anhydrase and other red blood cell components.
• This approach enhances the understanding of drug concentration-response relationships for acetazolamide.